Join our Stock Market News Group at GetPaidIndia on Telegram and WhatsApp.

This website is purely ACADEMIC in nature and NOT a stock market recommendation service or a tip provider. No live data or feeds are provided and all information is historic only. Information is provided for ease of understanding for the purpose of learning. Accuracy of definitions etc is not mantained. I am not a SEBI or IRDA registered.

Sun Pharmaceutical Industries Ltd



From GetPaidIndia.com
Jump to:navigation, search

BSE Data

  • Security ID: SUNPHARMA
  • Group / Index: A / S&P BSE SENSEX
  • Face value: 1.00
  • Security Code: 524715
  • ISIN: INE044A01036
  • Industry: Pharmaceuticals

In The News

Market Capitalization

Related Lesson: Why is Market Capitalization and stock liquidity important for the investor?

Markets Mojo

Date Quality Valuation Fin Trend
December 28, 2017 Good (Rank # 17 of 170 ) Fair Negative (Score: -19 )
November 21, 2017 Excellent (Rank # 17 of 169 ) Fair Very Negative (Score: -19 )
October 6, 2017 Excellent (Rank # 17 of 165 ) Fair Very Negative (Score: -23 )
July 7, 2017 Good (Rank # 8 of 164 ) Very Attractive Negative (Score: -13 )
Feb 20, 2017 Excellent Very Attractive Flat

Technical Indicators

Date Present Super Trend Trend Reversal PSAR Williams %R (14) CCI (20) ADX (14)
December 28, 2017 Bullish 500.56 Bullish -12.14 Overbought (Bearish) +266 Strong Uptrend (Bullish) 18.30 Weak Trend (Bearish)
August 3, 2017 Bearish 586.70 Bearish -90.05 (Neutral) -201 Strong Downtrend (Negative) 27.80 (Neutral)
July 14, 2017 Bearish 583.54 Bullish -14.99 (Neutral) +148 Strong Uptrend (Bullish) 25.30 (Neutral)
July 13, 2017 Bearish 583.54 Bullish -24.61 (Neutral) +131 Strong Uptrend (Bullish) 24.39 (Neutral)
July 12, 2017 Bearish 583.54 Bullish -26.17 (Neutral) +136 Strong Uptrend (Bullish) 23.92 (Neutral)
July 11, 2017 Sell 583.54 Buy -19.81 Overbought (Sell) +173 Strong Uptrend (Buy) 23.75 (Neutral)
July 10, 2017 Sell 583.54 Buy -18.29 Overbought (Sell) +190 Strong Uptrend (Buy) 23.56 (Neutral)
July 7, 2017 Bearish 583.54 Bullish -31.28 (Neutral) +76 (Neutral) 23.36 (Neutral)

Chart Frequency: 1 Day; Chart Style: Heikin Ashi

SuperTrend Parameters: Period: 7; Multiplier: 3

Parabolic SAR: Minimum AF: 0.02; Maximum AF: 0.2

Financial Results

Analyst / Broker comments on the stock

Ratings / Rankings

Date Source Ranking Description
November 24, 2017 Angel Broking Buy Target of Rs 615
June 18 - 24, 2017 Smart Investment Smart Best Buy The scrip had also underperformed the market in past one year, falling 28.54% as against Sensex's 17.80% rise.The large-cap company has equity capital of Rs 239.93 crore. Face value per share is Re 1.Buy. Buy more at decline.
June 12 - 25, 2017 Dalal Street Investment Journal Reviews Despite reporting considerable losses, the company has narrowed its losses as compared to the previous year, which gives an indication that it is moving in positive direction, so we recommend investors to HOLD the stock.
June 12, 2017 New Dawn Treasure Hunt Jewel of the Crown
June 11 - 17, 2017 Smart Investment Script Watch A stronger ramp-up for these drugs along with progress on other specialty products including Tildrakizumab (expected launch in FY19 ) and Seceria (potential launch in late FY19) could provide confidence on specialty initiatives by Sun. The stock is worth accumulation.
April 2017 Sharekhan Value Guide - Stock Update CMP: 708; Target: 775; Recommendation: Buy
April 13, 2017 MoneyControl.com News / Reviews / Analysis Prefer Sun Pharmaceutical Industries, says Vijay Chopra
April 12, 2017 MoneyControl.com News / Reviews / Analysis Buy Can Fin Homes, HDFC Bank; sell Sun Pharmaceutical Industries: Ashwani Gujral
April 8, 2017 Angel Broking Technical Picks - Weekly Pivot Levels S2: 640; S1: 653; Pivot: 675; R1: 688; R2: 709
April 7, 2017 MoneyControl.com News / Reviews / Analysis Sell Aurobindo Pharma, Sun Pharma: Mitessh Thakkar
March 20 - April 2, 2017 Dalal Street Investment Journal Analysis Buy
March 19 - 25, 2017 Smart Investment High Risk High Return Shares There is movement in the stock after the USFDA said that it will lift the import ban on Sun Pharma's Mohali facility.
Mar 6 - 19, 2017 Dalal Street Investment Journal # 22 Super 50

Insider Trading / SAST

  • November 22, 2017: The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia

External Links